Abstract: A method for performing a simulation of a field having a subterranean formation is described. The method includes obtaining phase behavior data of subterranean fluids of the field, generating an equation of state (EOS) model of the fluids based on the phase behavior data, generating a Helmholtz free energy model that reproduces predictions of the EOS model over a pre-determined pressure and temperature range, and performing the simulation of the field using the Helmholtz free energy model. The method may further include reducing the EOS model to a reduced EOS model having a reduced number of components to represent the EOS model over a pre-determined pressure and temperature range, generating the Helmholtz free energy model based on the reduced EOS model, and obtaining and using phase behavior data of injection fluids used. A computer system data.

Abstract: An introducer tool including a housing, a sheath detachably coupled to the housing, and a needle fixed to the housing. The housing can include a guidewire actuating mechanism configured to extend and retract a guidewire fixed to the guidewire actuating mechanism. The sheath can include a handle, and can be detachably coupled to the housing in a first configuration of the introducer tool designed for venous introduction of the sheath. An end portion of the needle can extend past an end portion of the sheath in the first configuration of the introducer tool. Methods for venous access including obtaining and using the introducer tool are also disclosed.

Abstract: An optical assembly includes an optically transparent substrate and a first lens removably coupled with the optically transparent substrate by one or more adhesive layers. The one or more adhesive layers are positioned between the optically transparent substrate and the first lens. Also disclosed are an eye-tracker and a display device, each of which includes the optical assembly.

Abstract: A computer-implemented American soccer training and evaluation method that includes subjecting a drilling user to pre-defined drilling protocol(s) of a plurality of American soccer drilling assemblies and obtain, from each pre-defined drilling protocol(s) of the plurality of American soccer drilling assemblies and from at least one sensor on each of the assemblies, at least one user physical characteristic of the drilling user. The user physical characteristic is communicated to an administrative server over a network, where it is stored and used to create a drilling user performance profile having individualized performance comparisons with respect to the at least one user physical characteristic of the drilling user and a performance benchmark. Then, the drilling user performance profile is communicated to to at least one of a plurality of electronic computing devices of a plurality of consuming users for evaluation and review.

Abstract: The present invention relates to compounds of formula (I)-(VI) and/or (A)-(H-I), or any subgenera thereof, or a pharmaceutically acceptable salt, tautomer or stereoisomer. The compounds of the present disclosure are useful in modulating androgen receptor activity and for treating cancer including prostate cancer.

Abstract: Compounds having a structure of formula (I), (I-A), (Ia)-(Ie), (A)-(E), and (II) or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof are provided. Uses of such compounds for modulating androgen receptor activity, imaging diagnostics in cancer and therapeutics, and methods for treatment of disorders including prostate cancer are also provided.

Abstract: Compounds having a structure of Formula I: or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1, R2, L1, L2, L3, X, a, b, c, n, and m are as defined herein, are provided. Uses of such compounds for modulating androgen receptor activity and uses as therapeutics as well as methods for treatment of subjects in need thereof, including prostate cancer are also provided.

Abstract: Compounds having a structure of Formula I: or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1, R2, R3, R11a, R11b, R11c, R11d, X, n1, n2, and n3 are as defined herein, are provided. Uses of such compounds for modulating androgen receptor activity, imaging diagnostics in cancer and therapeutics, and methods for treatment of subjects in need thereof, including prostate cancer are also provided.

Abstract: Compounds having a structure of Formula I, or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1, R2, L1, L2, L3, X, a, b, c, n, and m are as defined herein, are provided. Uses of such compounds for modulating androgen receptor activity and uses as therapeutics as well as methods for treatment of subjects in need thereof, including prostate cancer are also provided.

Abstract: A transfer conveyor assembly for a screening apparatus includes at least one transfer conveyor that is oriented transversely with respect to a feed direction of the screening apparatus and is configured to receive material from at least one respective screen deck of the screening apparatus. At least one intermediate transfer conveyor is positioned with respect to at least one further screen deck of the screening apparatus to receive material from the at least one further screen deck to feed material to a position away from the at least one transfer conveyor in a discharge direction of the screening apparatus.

Abstract: Compounds having a structure of Formula I: or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1, R2, R3, R11a, R11b, R11c, R11d, X, n1, n2, and n3 are as defined herein, are provided. Uses of such compounds for modulating androgen receptor activity, imaging diagnostics in cancer and therapeutics, and methods for treatment of subjects in need thereof, including prostate cancer are also provided.

Abstract: Compounds having a structure of Formula I, or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1, R2, L1, L2, L3, X, a, b, c, n, and m are as defined herein, are provided. Uses of such compounds for modulating androgen receptor activity and uses as therapeutics as well as methods for treatment of subjects in need thereof, including prostate cancer are also provided.

Abstract: Compounds having a structure of Formula I: or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1, R2, R3, R11a, R11b, R11c, R11d, X, n1, n2, and n3 are as defined herein, are provided. Uses of such compounds for modulating androgen receptor activity, imaging diagnostics in cancer and therapeutics, and methods for treatment of subjects in need thereof, including prostate cancer are also provided.

Abstract: Compounds having a structure of Formula I: wherein G, a, Q, L2, R1, R2, R3, R4, R5 and R6 are as defined herein are provided. Uses of such compounds for treatment of various indications, including prostate cancer as well as methods of treatment involving such compounds are also provided.

Abstract: Compounds having a structure of Formula I, or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1, R2, L1, L2, L3, X, a, b, c, n, and m are as defined herein, are provided. Uses of such compounds for modulating androgen receptor activity and uses as therapeutics as well as methods for treatment of subjects in need thereof, including prostate cancer are also provided.

Abstract: A transfer conveyor assembly for a screening apparatus includes at least one transfer conveyor that is oriented transversely with respect to a feed direction of the screening apparatus and is configured to receive material from at least one respective screen deck of the screening apparatus. At least one intermediate transfer conveyor is positioned with respect to at least one further screen deck of the screening apparatus to receive material from the at least one further screen deck to feed material to a position away from the at least one transfer conveyor in a discharge direction of the screening apparatus.

Abstract: A mobile screening apparatus includes a support chassis. The support chassis is configured for carrying at least one screening assembly having a top screen deck and at least one further screen deck below the top screen deck. At least at least one primary feed mechanism is configured for arrangement in communication with any one or more of the top and further screen decks to feed material to be screened onto said any one or more of the top and further screen decks.

Abstract: This invention provides compound having a structure of Formula I or Formula II. Uses of such compounds for treatment of various indications, including prostrate cancer as well as methods of treatment involving such compounds are also provided.

Abstract: Compounds having a structure of Formula I: or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1, R2, R3, R4, R5, X1, X2, X3 and X4 are are as defined herein, and wherein the compound comprises at least one F, Cl, Br, I or 123I moiety, are provided. Uses of such compounds for imaging diagnostics in cancer and therapeutics methods for treatment of subjects in need thereof, including prostate cancer as well as methods and intermediates for preparing such compounds are also provided.

Abstract: Compounds having a structure of Formula I: or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1, R2, R3, R4, R5, X1, X2, X3 and X4 are as defined herein, and wherein the compound comprises at least one F, Cl, Br, I or 123I moiety, are provided. Uses of such compounds for imaging diagnostics in cancer and therapeutics methods for treatment of subjects in need thereof, including prostate cancer as well as methods and intermediates for preparing such compounds are also provided.